ESR1 and breast carcinoma: The majority of breast cancers that metastasize to bone are estrogen receptor (ER)-positive so it is also interesting that activation of the CaSR has been shown to increase ER transcriptional activity and enhance the effects of estradiol in MCF-7 cells (Journe et al., 2004; Leclercq, 2012).